Patents Assigned to Octapharma AG
  • Patent number: 6893856
    Abstract: Disclosed is a process for preparing agents containing virus-inactivated vitamin K-dependent plasma components as well as protein C, protein S, factors II, VII, IX and/or X as well as combinations thereof, such as, for example, PPSB preparations, wherein a source containing these components is subjected to a appropriate separation procedures, especially by using membrane-chromatographic methods.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: May 17, 2005
    Assignee: Octapharma AG
    Inventors: Djuro Josic, Ales Strancar
  • Patent number: 6777541
    Abstract: The present invention relates to a process for the preparation of a solution comprising a substantially pure isoform of AT-III, said process comprising separating the isoform AT-III&agr; from AT-III&bgr; on a calcium hydroxyphosphate-based adsorbent.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: August 17, 2004
    Assignee: Octapharma AG
    Inventor: Göran Karlsson
  • Publication number: 20030191292
    Abstract: Filtration methods comprise virus-filtering a solution containing a least one macromolecule. The total salt content of the solution for virus-filtering is within the range of from about 0.2 M up to saturation with the salt. Salts that can be used in the filtering methods include sodium chloride, potassium chloride, sodium acetate, sodium citrate, sodium phosphate, potassium dyhydrophosphate and combinations thereof.
    Type: Application
    Filed: November 26, 2002
    Publication date: October 9, 2003
    Applicant: Octapharma AG, a Corporation of Switzerland
    Inventor: Stefan Winge
  • Patent number: 6528246
    Abstract: A method for the inactivation of viruses, in particular those having no lipid coats, in protein-containing compositions from blood, blood plasma or similar natural sources by treating said source, simultaneously or succesively, with an effective amount of dialkyl or trialkyl phosphates and optionally surfactants at an elevated temperature in the range of from 55° C. to 67° C. for five hours to 30 hours.
    Type: Grant
    Filed: September 28, 1995
    Date of Patent: March 4, 2003
    Assignee: Octapharma AG
    Inventors: Monika Stadler, Horst Schwinn, Djuro Josic, Werner Gehringer, Frederic Bal
  • Patent number: 6518406
    Abstract: The present invention relates to methods for purification of antithrombin-III (AT-III) by precipitation of impurities. The said methods comprise (a) adding, to a solution comprising antithrombin-III, a saccharide and citrate, in an amount sufficient for impurities to precipitate while antithrombin-III essentially remains in solution; (b) allowing impurities to precipitate; and (c) removing the precipitated impurities, thereby obtaining a solution comprising purified antithrombin-III. The invention also relates to pharmaceutical compositions, obtainable by the said methods, comprising purified antithrombin-III, as well as to reconstituted pharmaceutical compositions essentially free from visible particles.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: February 11, 2003
    Assignee: Octapharma AG
    Inventor: Stefan Winge
  • Publication number: 20020182195
    Abstract: A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.
    Type: Application
    Filed: April 8, 2002
    Publication date: December 5, 2002
    Applicant: Octapharma AG
    Inventors: Wolfgang Marguerre, Tor-Einar Sve
  • Publication number: 20020182582
    Abstract: Disclosed is a process for preparing agents containing virus-inactivated vitamin K-dependent plasma components as well as protein C, protein S, factors II, VII, IX and/or X as well as combinations thereof, such as, for example, PPSB preparations, wherein a source containing these components is subjected to a appropriate separation procedures, especially by using membrane-chromatographic methods.
    Type: Application
    Filed: May 2, 2002
    Publication date: December 5, 2002
    Applicant: Octapharma AG
    Inventors: Djuro Josic, Ales Strancar
  • Publication number: 20020061842
    Abstract: The invention concerns a method for preparing native collagen, comprising pretreatment of the collagen in a mixer with double transverse cutters equipped with a system controlling agitating and shearing velocity and a thermostat, and a subsequent step of sterilizing the collagen in liquid medium. The invention also concerns a sterile collagen, in particular a collagen mostly of type I, in native state and in particular pharmaceutical and/or parapharmaceutical and/or medico-surgical and/or ophthalmologic and/or cosmetic compositions and applications thereof.
    Type: Application
    Filed: July 30, 2001
    Publication date: May 23, 2002
    Applicant: OCTAPHARMA AG
    Inventor: Hamza Mansour
  • Patent number: 6136865
    Abstract: A method for reduction of the viral infectiousness of potentially infectious material, such as human or animal body fluids or fractions derived therefrom from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses characterized in thatsaid potentially infectious material for the isolation of said biologically active substances is treated witha hydrophobic phase which is essentially insoluble in water and is capable of forming a two-phase system with said potentially infectious material, andsaid hydrophobic phase is separated from the potentially infectious material thus treated.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 24, 2000
    Assignee: Octapharma AG
    Inventors: Lothar Biesert, Horst Schwinn, Wolfgang Marguerre
  • Patent number: 6057164
    Abstract: The method for the aptitude testing of protein fractions containing factor VIII the further processing of which comprises a pasteurizing step is performed in such a way that the starting material is examined for fragments within a range of from 20 to 50 kD. Fragments of factor VIII within this range evidently cause inhibitor formations in patients pretreated with factor VIII. Batches contaminated with such fragments can also be utilized, i.e., for the preparation of a high purity virus-free factor VIII by size exclusion chromatography on hydrophilic materials.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: May 2, 2000
    Assignee: Octapharma AG
    Inventors: Andrea Buchacher, Monika Stadler, DJuro Josic
  • Patent number: 6007979
    Abstract: A method for reduction of the viral infectiousness of potentially infectious material, such as human or animal body fluids or fractions derived therefrom from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses characterized in thatsaid potentially infectious material for the isolation of said biologically active substances is treated witha hydrophobic phase which is essentially insoluble in water and is capable of forming a two-phase system with said potentially infectious material, andsaid hydrophobic phase is separated from the potentially infectious material thus treated.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: December 28, 1999
    Assignee: Octapharma AG
    Inventors: Wolfgang Marguerre, Horst Schwinn, Lothar Biesert
  • Patent number: 5919909
    Abstract: A process for the preparation of factor IX from a biological source by chromatography involves prior treatment with ammonium sulfate as a protein precipitant at a concentration of from 1.5-2.3 mol/l.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: July 6, 1999
    Assignee: Octapharma AG
    Inventors: Djuro Josic, Lutz Hoffer, Frank Morfeld
  • Patent number: 5714590
    Abstract: Described is an economical process for the recovery of factor VIII from blood plasma or cryoprecipitate. In the process, anion exchanger chromatography is conducted using a separating material based on carriers containing hydroxyl groups, the surfaces of which carriers have been coated with covalently boded polymers. The polymers contain repeating units represented by formula (I).
    Type: Grant
    Filed: August 29, 1994
    Date of Patent: February 3, 1998
    Assignee: Octapharma AG
    Inventors: Monika Stadler, Horst Schwinn
  • Patent number: 5648472
    Abstract: This invention describes a process for preparing virus-inactivated immunoglobulin solutions suitable for intra-venous application, characterized in that the immunoglobulin is treated with non-ionic surfactants which subsequently are removed by solid-phase extraction on hydrophobic materials.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: July 15, 1997
    Assignee: Octapharma AG
    Inventors: Werner Gehringer, Patrick Selosse
  • Patent number: 5328694
    Abstract: A stable, injectable solution containing factor VIII suitable for the treatment of humans, natural or synthetic disaccharides, preferably saccharose, in concentrations of from 0.1 to 0.65 mol/1, and one or more amino acids in concentrations of from 0.1 to 1.0 mol/1. A process for preparing same and the use of natural or synthetic disaccharides, preferably saccharose, and one or more amino acids for stabilizing factor VIII.
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: July 12, 1994
    Assignee: Octapharma AG
    Inventor: Horst Schwinn